Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration.
Aciont is awarded a phase I SBIR $214K grant for the project titled "Novel Method for the Ocular Iontophoretic Delivery of Avastin® and Lucentis®".
The National Eye Institute (NEI) in conjunction with the Office of the Director of the National Institutes of Health awarded a $214K (two hundred and ...
Satisfied Users & 
Approved Press Releases
